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ABSTRACT
Aims: To construct and compare a partitioned-survival analysis (PartSA) and a semi-Markov multi-state
model (MSM) to investigate differences in estimated cost effectiveness of a novel cancer treatment
from a UK perspective.
Materials and Methods: Data from a cohort of late-stage cancer patients (N> 700) enrolled within a
randomized, controlled trial were used to populate both modelling approaches. The statistical software
R was used to fit parametric survival models to overall survival (OS) and progression-free survival (PFS)
data to inform the PartSA (package “flexsurv”). The package “mstate” was used to estimate the MSM
transitions (permitted transitions: (T1) “progression-free” to “dead”, (T2) “post-progression” to “death”,
and (T3) “pre-progression” to “post-progression”). Key costs included were treatment-related (initial,
subsequent, and concomitant), adverse events, hospitalizations and monitoring. Utilities were stratified
by progression. Outcomes were discounted at 3.5% per annum over a 15-year time horizon.
Results: The PartSA and MSM approaches estimated incremental cost-effectiveness ratios (ICERs) of
£342,474 and £411,574, respectively. Scenario analyses exploring alternative parametric forms provided
incremental discounted life-year estimates that ranged from þ0.15 to þ0.33 for the PartSA approach,
compared with 0.13 to þ0.23 for the MSM approach. This variation was reflected in the range of
ICERs. The PartSA produced ICERs between £234,829 and £522,963, whereas MSM results were more
variable and included instances where the intervention was dominated and ICERs above £7 million
(caused by very small incremental QALYs).
Limitations and conclusions: Structural uncertainty in economic modelling is rarely explored due to
time and resource limitations. This comparison of structural approaches indicates that the choice of
structure may have a profound impact on cost-effectiveness results. This highlights the importance of
carefully considered model conceptualization, and the need for further research to ascertain when it
may be most appropriate to use each approach.
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In 2017, there were an estimated 24.5 million incident cases
of cancer globally and 9.6 million cancer deaths1. It is the
second leading cause of death globally and cancer deaths
are predicted to rise globally to 16.3 million by 20402,3.
Cancer can be severely debilitating (particularly for those
with progressed disease), often with a profound impact on
patient and carer quality of life4,5. In addition, cancer is often
associated with substantial financial burden causing distress
for patients, caregivers, and dependents6,7.
Since the turn of the century, there has been a rapid
development in the range of innovative treatments available
to treat patients with cancer by improving survival and qual-
ity of life. However, such treatments often come at a high
cost. With an ever-increasing demand for new, effective
treatments within the constraints of a finite healthcare
budget, decision modelling plays an important role in the
estimation of the value of these new cancer treatments.
Cost-effectiveness analysis (CEA) provides decision makers
with an objective basis from which decisions may be
informed. Typically, a CEA involves the development of an
economic model to synthesize the available evidence con-
cerning costs and effects in order to compare alternative
treatment strategies. The most common model structures
constructed in the field of oncology are partitioned survival
analyses (PartSA) and state transition models (STMs), which
are frequently based on three health states relevant to can-
cer: pre-progression, progressed disease and death8,9.
In the three-state structure, PartSA requires two outcomes
(progression-free survival (PFS) and overall survival (OS)) to
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inform health state occupancy, with time in the progressed
disease state inferred through the difference between the
two outcomes. PFS and OS outcomes are often readily avail-
able from the literature and are widely understood by clini-
cians and other stakeholders. This makes the PartSA a
practical model choice, which is likely to be one reason that
this structure was found to be the most common structure
applied for cancer treatments in health technology assess-
ments (HTAs) submitted to the National Institute for Health
and Care Excellence (NICE) – the HTA body for England
and Wales8,9.
Conversely, STMs require specific information relating to
the three transitions possible between the health states.
When patient-level data are available this requirement is sim-
ple to fulfil. However, often these data are unavailable for
comparators outside of a pharmaceutical company’s clinical
trial. As an additional complexity, STMs can be further div-
ided based on discrete-time/continuous-time, Markov/semi-
Markov or cohort/patient level. Multi-state modelling (MSM)
falls under the STM bracket and could be considered when
there are a series of competing events and when these
events occur sequentially. In the three-state cancer model,
progression and death are competing events and could
occur sequentially, thus MSM is a suitable modelling method
for consideration in cancer. The MSM approach models each
of the transitions of interest simultaneously and uses a con-
tinuous-time framework.
A review of published CEAs in cancer found that despite
the modelling structures available, typically only one is pre-
sented with limited explanation as to the justification and
validation of this choice8. This is despite guidance from the
Decision Support Unit (DSU) supporting NICE in UK HTAs
stating that “state transition modelling should be used
alongside the PartSA approach to assist in verifying the
plausibility of PartSA’s extrapolations and to address uncer-
tainties in the extrapolation period”9.
There is limited research considering the impact of differ-
ent structural assumptions within economic models of cancer
treatments. Studies that have been published highlight a dis-
crepancy in results across the different approaches, suggest-
ing that model structure may influence conclusions of
clinical- and cost-effectiveness:
 Williams et al. (2017) considered a case study in first-line
chronic lymphocytic leukemia comparing outcomes from
a PartSA, a discrete-time semi-Markov STM and a continu-
ous-time semi-Markov (i.e. MSM) STM – results approxi-
mated ICERs of: £16,000, £13,000 and £29,000
respectively10.
 Degeling et al. (2018) compared the use of a cohort dis-
crete-time STM with a discrete event simulation STM in
patients with metastatic colorectal cancer; estimated
ICERs were e172,443 and e168,383, respectively11.
 Gibson et al. (2019) and Gibson et al. (2018) considered a
PartSA, a discrete-time Markov STM and a patient level
simulation STM to assess the value of immuno-oncology
therapies in metastatic melanoma12,13. Both studies also
explored extending the standard three state oncology
model by including an immune-specific health state.
Results were discrepant between the different model
structures with incremental cost-effectiveness ratios
(ICERs) varying between £6,474 and £49,000
 Smare et al. (2020) compared the use of a PartSA to two
variations of a semi-Markov STM for a treatment for renal
cell carcinoma and found that model structure varied esti-
mated survival benefit by up to 14%14.
The studies published to date emphasize the importance
of justifying and validating the choice of model structure.
Ideally, for each CEA, all suitable model structures should be
considered, and results presented with an explanation as to
which best reflects the dynamics of the disease and treat-
ment pathway, with clinician input and external data sources
serving as a critical source of validation. However, there are
many reasons why this may not be standard practice; such
as, feasibility constraints (e.g. time and funding), challenges
acquiring patient-level data, and a lack of understanding
relating to the structural assumptions underpinning different
model structures.
The aim of this paper is to compare a PartSA and a semi-
Markov MSM STM approach as methods for estimating the
cost-effectiveness of a novel treatment compared to the
standard of care within the context of late-stage cancer. This
paper aims to add to the growing body of literature empha-
sizing the importance of justifying model structure and to
explore why these differences occur.
Data and methods
Data used for extrapolation
To inform both modelling approaches, data were sought to
populate the model transitions. While data could have been
developed using simulation methods, data collected as part
of a clinical trial were preferred in order to test the
approaches using “true” data. Data to compare modelling
approaches were provided to the authors under the proviso
that the treatments compared were anonymized.
A case study comprising of data from a randomized con-
trolled trial (RCT) comparing two treatments (TX1 vs. TX2) for
a type of late-stage cancer was used to compare the two
modelling frameworks (PartSA vs. MSM) – the average age of
patients was between 60 and 70. The RCT considered a large
cohort of patients (N> 700) and had a median follow-up of
approximately 15 months. At the end of follow-up between
50–70% patients had progressed and between 20–30% had
died across both the TX1 and TX2 arms, respectively.
Economic models
Both economic models were developed to compare the total
costs and quality-adjusted life-years (QALYs) associated with
TX1 and TX2 from a UK National Health Service (NHS) per-
spective, ultimately providing an ICER for TX1 vs. TX2. Costs
and QALYs were discounted using a rate of 3.5%, in line with
UK HTA requirements15. A 15-year time horizon was selected
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such that all patients had died in each model framework and
a monthly cycle length, across both modelled strategies.
Models were constructed in the statistical software R
version 3.0116. The code used is provided in the
Supplementary Material.
PartSA structure
The PartSA was characterized by three health states (pre-pro-
gression, progressed disease and death); this structure is the
most commonly seen in cancer submissions to NICE in the
UK8,9. State membership was determined by two independ-
ent survival curves (PFS and OS) that allow sub-division (or
“partitioning”) of the OS curve. Time dependency (i.e. the
relationship between time spent in a health state and the
probability of leaving that health state) is implicitly captured
within the PartSA framework. The model structure is pre-
sented in Figure 1.
Joint parametric models were fitted to the independent
PFS and OS outcomes using the phreg, aftreg and flexsurvreg
functions in R (using eha and flexsurv packages, respectively);
the proportional hazard assumption was considered appro-
priate following inspection of the log-cumulative hazard
plots and the Schoenfeld residual plots (Supplementary
Material). As per DSU guidance, six parametric distributions
were fit using the individual patient-level data for each trial
outcome: exponential, generalized gamma, Weibull, lognor-
mal, log-logistic and Gompertz17. Goodness of fit was based
on Akaike’s Information Criterion (AIC), Bayesian Information
Criterion (BIC) and visual comparison with Kaplan-
Meier estimates.
Statistically, the generalized gamma and the lognormal
provided plausible fits to the PFS data. Visual interpretation
indicated the lognormal to predict an implausibly wide tail.
The generalized gamma appeared to provide estimates that
better aligned with other literature in this disease area.
Therefore, the generalized gamma curve was selected to
model PFS outcomes in the base case. The goodness of fit
statistics indicated that the lognormal, log-logistic and
Weibull parametric curves provided plausible fits to the OS
data. Based on visual interpretation of the extrapolated
curves and comparison with other literature in this disease
area, the Weibull curve was applied in the base case. Out of
the three highlighted by the goodness-of-fit statistics, the
Weibull was the most pessimistic curve in terms of mean sur-
vival predicted. Therefore, this is considered a conservative
assumption. Alternative parametric curves are explored in
scenario analyses.
MSM structure
The MSM was also characterized by the same three health
states: progression-free, progressed disease and death. The
model structure is presented in Figure 2.
The MSM requires assessment of the Markovian assump-
tion; this assumption refers to the memoryless feature of a
Markov model i.e. transitions from a health state are inde-
pendent of the duration of time spent in the currently-occu-
pied or any previously-occupied health state(s). To assess the
applicability of this assumption, a Markov Cox proportional
hazards model was constructed. The model considered the
transition from progression to death explained by the time
spent in the previous health state. This covariate (time in the
Figure 1. PartSA model structure.
Figure 2. MSM model structure.
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previous state) was shown to be statistically significant
(p¼ .022); results indicated a longer duration spent in the
progression health state would increase the risk of death.
Therefore, a semi-Markov approach was undertaken, wherein
the time spent in the progression health state depends on
time spent in the pre-progression health state.
In line with the PartSA approach, joint parametric models
were fit to the data for each transition. Three survival models
were estimated (transition 1 [T1]: progression-free to pro-
gressed disease; transition 2 [T2]: progression-free to death
and transition 3 [T3]: progressed disease to death). The pub-
lished code from Williams et al. (2017) was adapted to this
dataset to estimate the transitions relevant to this MSM
structure18. The aforementioned standard six distributions
were considered for each transition. These methods are simi-
lar to the PartSA approach with one key difference: any
observation where an event occurs which is not the event of
interest for a specific transition is treated as a censored
observation i.e. patients that experience competing events
are treated in the same way as a patient that was lost to fol-
low-up. For example, for the transition from progression-free
to progressed [T1] any deaths reported in the data are not
the event of interest and so they are censored.
The MSM approach considered a continuous time structure
using the exact timing of transitions. However, for the purposes
of estimating mean survival using the area under the curve
approach, a monthly cycle length was applied. Due to compu-
tational issues with the generalized gamma and Gompertz dis-
tributions when fitting the transitions from progression-free to
progressed disease, the calculation of transition probabilities
with the MSM used cycle increments shorter than one month
(up to 1/72 of a month) for these distributions up to the 15-
year time horizon. This shortening of the cycle length was
needed to overcome a difficulty in meeting the requirement
that differences in cumulative hazards between consecutive
time points were below one (as is aligned with the approach
proposed by Williams et al. [2016])18.
The AIC and BIC provide us with information as to how
well the parametric curves fit the individual transitions.
However, the transitions do not correspond to the state occu-
pancy probabilities, which are defined by the competing risks
of progression and death. Therefore, the AIC and BIC meas-
ures need to be interpreted with caution in an MSM frame-
work as they do not account for the underlying relationships
between the transitions; transitions defined by AIC/BIC score
may not produce health state occupancies that provide a
good fit to the data. Parametric curves were selected based
on AIC, BIC and visual comparison with Kaplan–Meier esti-
mates. The generalized gamma was selected for T1 and the
Weibull was selected for T2 and T3. These base case paramet-
ric forms broadly align with those applied in the PartSA struc-
ture for PFS and OS outcomes, respectively. Alternative
parametric curves are explored in scenario analyses.
Cost and utility inputs
Table 1 presents the cost and quality of life inputs informing
the economic models. Costs applied within the models
included: drug, adverse event, concomitant medication, hos-
pitalization and subsequent therapy costs. It was assumed
that all patients remained on treatment until progression.
Therefore, all costs associated with treatment (drug, adverse
event, concomitant medication and hospitalization costs)
were accrued by patients in the pre-progression health
states. Only drug and hospitalization costs were dependent
on type of treatment. It was assumed that receipt of TX1 or
TX2 did not impact choice of subsequent therapy. This is a
simplification of the treatment pathway; in real-world clinical
practice subsequent therapies may differ between the treat-
ment arms. However, for the purposes of focusing on differ-
ences in model structure driving results, these costs have
been assumed to be equal. All patients in the progressed
disease health states accrued a weekly cost of subse-
quent therapy.
In reality, some costs may differ within a given health
state; for example: patients may discontinue treatment
before documented disease progression or toxicity profiles
may differ. However, these differential impacts were not
explored so that the impact of model structure on outcomes
could be clearly identified – without introducing additional
differences from cost inputs. In addition, both of these exam-
ples are expected to predominantly affect costs and effects
related to pre-progression disease which should be captured
reasonably well by both the PartSA and MSM approaches.
Quality of life was captured through the application of
health state specific utility values: 0.80 for pre-progression
and 0.60 for progressed disease. These inputs were applied
identically across both model structures. While inputs are
based on an approximation from the literature, these inputs
were considered to reflect patients with late-stage cancer
treated with TX1 and TX2.
Comparison of approaches
To understand the differences in the model approaches, the
occupancy of the model health states projected using each
approach were compared using Markov traces. Through
inspection of Markov traces, the proportion of patients resid-
ing within each health state may be established (regardless
of how long patients have been within a given state). This
approach allows for a more in-depth inspection of the
Table 1. Cost and utility inputs.
Parameter Value Frequency Health state applied
Drug costs
TX1 £6,000 Every 4-weeks Pre-progression
TX2 £4,000 Every 4-weeks
Adverse events £30 Weekly
Concomitant medications £50 Weekly
Hospitalizations
TX1 £100 Weekly Pre-progression
TX2 £130 Weekly
Subsequent therapy £500 Weekly Progressed disease
Utility values
Pre-progression 0.8 Constant Pre-progression
Progressed disease 0.6 Constant Progressed disease
Note: Cost and utility inputs are arbitrary parameters that were included to
broadly resemble values seen in a range of late-stage cancer models. Simple
assumptions informed these parameters such that this analysis could focus on
the comparison of model structures rather than model inputs.
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accrued life-years (LYs) in each model health state. After
comparing health state occupancy, the probability of resid-
ing within a given state was plotted over time to establish
differences in this outcome.
To contextualize the differences in the modelling
approaches, the costs and utility inputs described above
were used to produce CEA results. The values used to popu-
late these results are informed by simple assumptions rather
than robust data and are used to simply demonstrate how
the modelling approaches will affect modelled outcomes.
Results
The fitted PFS and OS curves for TX1 and TX2 under the
PartSA approach based on the generalized gamma and
Weibull functions, respectively, are presented in the
Supplementary Material. The Supplementary Material also
presents the fitted transitions for TX1 and TX2 under the
semi-Markov MSM approach.
Health state occupancy
Figure 3 presents the Markov traces for TX1 and TX2 for
each model structure (PartSA and MSM). Figure 4 then
presents the probability of residing in each of the health
states over time for each model structure. Table 2 presents
the undiscounted LYs accrued in each health state for
each structure.
Each of the model structures show similar predictions for
the within-trial period. However, after the end of follow-up,
there are clear differences between the results associated
with each structure; both in absolute terms (i.e. affecting
estimates for each treatment individually) and relative terms
(affecting the estimated incremental benefit).
The probability of residing in the pre-progression health
state is similar between the two model structures for each
treatment – this is partly explained by the same parametric
form which has been assumed for PFS and for T1 under the
two approaches (i.e. generalized gamma). While similar, the
MSM predicts slightly fewer LYs for both TX1 and TX2 and a
larger resulting difference in progression-free LYs (PFLYs) of
0.49 compared with 0.34 for the PartSA.
As seen for the progression-free state, the probability of
residing in the progressed disease health state is similar from
model baseline to 13 and 20months, for TX1 and TX2,
respectively. These timepoints coincide with the approximate
times until which data are available from the trial. However,
after these time points (i.e. in the extrapolation period), the
probability of residing in this health state continues to
increase under the PartSA structure and begins to decline
under the MSM structure. The probability of residing in the
progressed health state does eventually decline under the
Figure 3. Markov traces for TX1 and TX2 from the PartSA (3a and 3b, respectively) and MSM (3c and 3d, respectively) approaches.
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PartSA but at a later time point and at a slower rate than
the MSM structure.
The progressed disease LYs (PDLYs) are very different
under the two different model structures; the PartSA predicts
2.31 and 2.30 PDLYs for TX1 and TX2, respectively; whereas
the MSM predicts 1.19 and 1.37, respectively. The absolute
values are smaller under the MSM approach and the direc-
tion is reversed i.e. more PDLYs are accrued for TX2 than
TX1 under the MSM approach, whereas fewer PDLYs are
accrued for TX2 than TX1 under the PartSA approach.
Finally, as would be expected, due to the differences aris-
ing in the progressed disease health state, the probability of
remaining alive over time is higher under the PartSA
approach compared with the MSM approach – as described
by the total LYs: 5.02 and 4.66 for TX1 and TX2, respectively
derived from the PartSA approach and 3.86 and 3.55 for TX1
and TX2, respectively derived from the MSM approach. The
probability of being alive begins to diverge at 15 and
16months for TX1 and TX2, respectively (again, approxi-
mately in line with the end of the observed data period).
Figure 4. Probability of residing in each health state over time for TX1 (4a) and TX2 (4b) from the PartSA and MSM approaches, respectively.
Table 2. Undiscounted life-years.
Pre-progression Progressed disease Total
PartSA MSM PartSA MSM PartSA MSM
TX1 2.71 2.67 2.31 1.19 5.02 3.86
TX2 2.37 2.18 2.30 1.37 4.66 3.55
Incremental 0.34 0.49 0.01 0.18 0.36 0.31
Abbreviation. MSM, multi-state model; PartSA, partitioned survival analysis.
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Cost-effectiveness analysis results
Headline CEA results are presented in Table 3. Incremental
costs are estimated as £78,045 and £78,199 for the PartSA
and MSM approach, respectively; with incremental QALYs of
0.23 and 0.19, respectively. This results in ICERs of £3,42,474
(PartSA) and £4,11,574 (MSM).
The differences in the ICER are mostly driven by differen-
ces in incremental QALYs, which in turn are affected primar-
ily by differences in the overall LYs, and the split of LYs
between PFLYs and PDLYs estimated from the two model
structures (as described above). Health state specific costs
and QALYs are presented in Table 4.
While the incremental costs are similar, there are differen-
ces in terms of absolute total costs which will impact other
economic outcomes (including budget impact) depending
on which model structure is considered. The absolute costs
estimated with the MSM structure are lower than the PartSA
structure. This is due to a slightly smaller proportion of
patients residing in the progression-free health state over
time (accruing a lower total treatment cost), as well as a
smaller proportion of patients who are alive over time (accru-
ing fewer costs associated with any treatment and dis-
ease management).
Sensitivity analysis
A total of 36 scenarios were explored within the PartSA
structure, based on all possible combinations of the six
“standard” parametric curve choices applied to the OS and
PFS data (i.e. 6 6). The incremental costs and QALYs
derived from these scenarios are presented in Figure 5 –
these scenarios yielded ICERs ranging from £2,34,829 to
£522,963. PFLYs ranged from 1.63–2.59 for TX1 and
1.44–2.31 for TX2; PDLYs ranged from 0.78–4.78 for TX1 and
0.91–4.82 for TX2.
For the MSM structure, 216 scenarios were explored based
on different parametric curve choices applied to T1, T2 and
T3 (i.e. 6  6  6). The incremental costs and QALYs derived
from these scenarios are presented alongside the PartSA
scenarios in Figure 5. These scenarios yielded results ranging
from TX2 being dominant, to TX1 being associated with an
ICER of £7,695,487. High ICERs are caused by very small
incremental QALYs being estimated in some scenarios.
Table 3. Headline CEA results.
Model approach Total Incremental ICER
Costs QALYs Costs QALYs
PartSA
TX1 £265,693 3.14
TX2 £187,648 2.91 £78,045 0.23 £3,42,474
MSM
TX1 £239,499 2.57
TX2 £161,300 2.38 £78,199 0.19 £4,11,574
Abbreviations. CEA, cost-effectiveness analysis; ICER, incremental cost-effective-
ness ratio; MSM, multi-state model; PartSA, partitioned survival analysis; QALY,
quality adjusted life year.
Figure 5. Scenario analyses associated with parametric forms.
Table 4. Disaggregated model costs and outcomes.
Discounted
outcomes
Pre-progression Progressed disease Total
PartSA MSM PartSA MSM PartSA MSM
Costs
TX1 £2,14,316 £2,11,674 £51,377 £27,825 £2,65,693 £2,39,499
TX2 £1,36,146 £1,28,387 £51,502 £32,913 £1,87,648 £1,61,300
QALYs
TX1 1.96 1.93 1.18 0.64 3.14 2.57
TX2 1.73 1.63 1.18 0.76 2.91 2.38
Abbreviaions. CEA, cost-effectiveness analysis; ICER, incremental cost-effective-
ness ratio; MSM, multi-state model; PartSA, partitioned survival analysis; QALY,
quality adjusted life year.
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PFLYs ranged from 1.58-2.51 for TX1 and 1.38-2.21 for TX2;
PDLYs ranged from 1.05-1.97 for TX1 and 1.24-2.15 for TX2.
Figure 5 demonstrates a higher spread of uncertainty in
terms of parametric curve selection from the MSM structure
compared with the PartSA structure – this may be explained
by the fact that the MSM structure specifies the model based
on more specific data for each transition (three transitions
vs. two endpoints in the PartSA structure using the same
data source). Additionally, varying T1 has a “knock-on” effect
within the model due to the embedded structural links; this
transition directly impacts the proportion of patients eligible
for T2 and T3. Therefore, varying the parametric curve
informing T1 will likely have an amplified effect on the
model results. The scenarios associated with the MSM struc-
ture are largely to the left of the scenarios associated with
the PartSA structure, indicating that MSM scenarios predicted
fewer incremental QALYs.
Summary of key differences
The key differences between the model structures are driven
by differences in estimated outcomes beyond the duration
of follow up. The MSM structure predicts a lower probability
of being in the progressed disease state over time from 13
to 20 months for TX1 and TX2, respectively and a higher
probability of being in the death health state from 15 to
16months, respectively. These differences have implications
for both the total costs and total QALYs accrued, which then
go onto impact the ICER. The sensitivity analysis results illus-
trated a broad spread of estimated costs and QALYs, with
the MSM scenarios generally predicting fewer incremen-
tal QALYs.
Discussion
The PartSA is the most commonly applied model structure in
oncology within the UK. However, the limitations associated
with this structure are often not acknowledged or explored
thoroughly8. Use of MSMs in HTA are less common, a recent
example considering the structural link between progression
and death through MSM is described in the UK HTA NICE
submission TA58719. The comparison of modelling
approaches (PartSA vs. semi-Markov MSM) indicates that the
choice of structure can have a profound impact on predicted
outcomes and cost-effectiveness results which may subse-
quently impact reimbursement decisions made by HTA
bodies. Given these differences it is important to understand
the assumptions underpinning each structure.
The PartSA extrapolates PFS and OS independently; and
so, mortality in this structure is only determined by time to
death data and is not explicitly linked to earlier progression
events. The assumption that the modelled survival endpoints
are structurally independent is potentially problematic as
there are a number of dependencies between the survival
endpoints, for example: (1) they include some of the same
events (e.g. PFS and OS curves include the same pre-progres-
sion deaths); (2) events are structurally dependent (e.g. death
cannot be followed by progression and time spent
progression-free contributes to time spent alive); and (3)
intermediate events are often of prognostic importance for
later events (e.g. progression is generally considered a nega-
tive prognostic factor for mortality)9. For the within-trial
period, these dependencies are reflected in the data and
should be closely reflected in the PartSA results. However,
for analyses that model beyond the trial period, dependen-
cies between endpoints are ignored with potentially import-
ant implications for extrapolation. Around 60% of patients in
the dataset informing this research had progression events
at data cut-off. Therefore, ignoring the dependences
between endpoints is likely to impact the validity of extrapo-
lated outcomes.
Conversely, the MSM approach models clinical events
such that they are explicitly related. Note: there remains
uncertainty within the MSM associated with extrapolating
outcomes from immature data, for example: the probability
of transitioning from progressed disease to death will
encompass uncertainty if not all patients have progressed
within the data set. Additionally, the MSM has the potential
to model counterfactuals regarding the patterns of treatment
post-progression which may offer a better reflection of the
outcomes observed in clinical practice. In the three-state
example presented in this paper, external data sources of
post-progression survival could directly inform transition 3 of
the MSM. Whereas, these data would have to be combined
with the OS outcomes informing the PartSA.
The MSM approach is not without limitations. Currently,
available analytical methods rely on access to individual-level
data for the treatments of interest, which are unlikely to be
available for published clinical studies. Furthermore, as with
standard STMs, the MSM approach requires sufficient data to
inform the transitions from progression-free to death and
progressed disease to death. Data on these transitions specif-
ically are often limited if the majority of deaths occur after
disease progression or when follow-up is limited.
Within the context of a clinical trial, data following disease
progression are often restricted due to limited follow-up.
This limitation is sometimes used in defense of a model
approach that does not require these data specifically (i.e. a
PartSA). However, while a PartSA can (in theory) be fitted to
any dataset where PFS and OS are available, this does not
mean that the outcomes are robust.
From a feasibility stance, MSMs are objectively more com-
plex and time-consuming to develop. However, the analysis
and code relating to the msm R package is explained in detail
by Williams et al. alongside a worked example18. Once this
code is understood (requiring working knowledge of R pro-
gramming), it is relatively simple to adapt and apply to other
settings. To further encourage use and transparency in this
area, we have also published our code in the Supplementary
Material for both the PartSA and MSM frameworks.
A PartSA informed by sufficiently robust data should yield
very similar outcomes to the MSM framework. However,
where data are limited (e.g. due to administrative censoring),
it is likely that each approach will yield different estimates of
post-progression survival. Rigorous model calibration and
validation from clinical experts can help to align the
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post-progression survival with real world experiences.
However, without more data, there is only so much model
calibration can achieve. There are published guidelines avail-
able for choosing a model structure based on key require-
ments (including: output requirements, population size and
system complexity)20. However, to date, there is no pub-
lished validation tool to assess the relative fit of two or more
model structures – this is an unmet need for model develop-
ers which should be addressed in future research.
The key differences between the model structures are
driven by the estimated outcomes beyond the trial follow-
up; the example presented in this paper considers a 15-year
time horizon, given that the median follow-up of the trial is
15-months, predicted outcomes inform the majority of the
model time horizon. The 15-year time horizon aligns with
HTA guidelines for life-extending treatment i.e. the time hori-
zon should be long enough to reflect all important differen-
ces in costs or outcomes between the technologies being
compared15. Extrapolating beyond the trial follow-up intro-
duces uncertainty into the model estimates. Therefore,
shorter time horizons, with less uncertainty, may be consid-
ered in scenario analyses. However, it is important to note
that these shorter time horizons would likely not reflect all
the benefits or costs that would be accrued by the treatment
and, as such, would not be the “true” ICER.
This analysis presents deterministic results. Probabilistic
results are often important for decision making to assess the
impact of uncertainty on the dispersion of results. However,
these were outside of the scope of this example. In practice,
is important that probabilistic analyses conducted within
both the PartSA and MSM framework account for the correl-
ation between endpoints and transition probabilities such
that clinically implausible results are not generated (e.g. PFS
curves crossing OS curves).
There is insufficient information available to inform our
analysis in order for us to conclusively make a recommenda-
tion as to which of the presented models is the “least
wrong”, with the understanding that no health economic
model is “right”. It is likely that there is uncertainty intro-
duced within the PartSA structure due to the immature sur-
vival data yet understanding the extent of this is difficult
without further information on long-term outcomes.
Similarly, transitions from the progressed disease to death
health state in the MSM framework are based on limited fol-
low-up from a subgroup of patients who have progressed
within the clinical trial. Therefore, these data are also likely
to lead to somewhat uncertain estimates of OS.
In the absence of longer follow-up from the trial, external
data sources may be considered (where available). These
sources can be used as a validation tool or directly built into
the modelling framework. The MSM structure lends itself to
the implementation of external data sources for the T2 tran-
sition, from progressed disease to death. However, given
that outcomes are not modelled explicitly for patients with
progressed disease in the PartSA approach, it is not possible
to incorporate such external data in this framework.
Our analysis has used “real” data from a late-stage cancer
clinical trial, simulating a “real-world” scenario where only
immature data are available. The methods and results have
been clearly explained such that the analyses can be easily
repeated, additionally, the R code has been made available
to encourage this. However, the research has limitations.
Firstly, directional findings from our study are specific to the
setting in which the clinical trial is set. Limited information
has been provided on the disease area and the clinical trial
due to confidentiality requirements from the pharmaceutical
company. However, this does not impact the conclusions of
the study in relation to model structures. Additionally, the
research is limited to exploring a three-state oncology model
structure for both PartSA and MSM – MSMs may be consid-
ered as a better option when the causal pathway is more
complicated. The clinical data used in this study are limited.
Having a longer follow-up from the clinical trial would pro-
vide more information as to which model is predicting the
outcomes closest to reality. Future research could explore
the impact of follow-up time on the robustness of the
results; for example, censoring patients at shorter follow-up
times or limiting the analyses to subgroups with different fol-
low-up times. It would also be beneficial to re-visit these
analyses with longer term data to see which model was pre-
dicting outcomes in line with observed data. In addition, we
have only considered relatively “simple” parameterizations
for each transition/curve used in both modelling approaches
due to currently-available packages for the MSM approach.
Further research is required to understand which model
should be used and when, in terms of different contexts and
settings8. However, it is important that for now, we under-
stand the implications of the different modelling methods
and sufficiently explore these such that decisions remain evi-
dence based and allow for the most efficient allocation of
resources. In relation to MSM structures specifically, research
should consider how to incorporate relative efficacy for treat-
ments which only have OS and PFS outcomes reported in
the literature. In terms of deciding the most appropriate
model structure, it is important to acknowledge that no one
approach will be without limitations. Therefore, we recom-
mend that researchers state and discuss the assumptions
and drawbacks featured for their chosen model structure(s) –
the NICE Technical Support Documents provide a useful
starting point as to what should be presented for each mod-
elling approach9. Ideally, multiple model structures should
be developed, and the relative advantages and limitations
associated with each approach stated and explored in scen-
ario analyses. Recommendations for decision makers using
health economic models to inform allocative decisions are to
explore how the assumptions underpinning the model struc-
ture may be influencing results and, where there are insuffi-
cient data to support the underlying structures, to be
cautious when interpreting results.
Conclusions
This analysis adds to the growing literature demonstrating
the importance of justifying the underlying model structure
and exploring structural assumptions within scenario analy-
ses. We recommend that where feasible a comparison of
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model structures is made and further research to ascertain
when it may be most appropriate to use each approach. In
terms of contemporary HTA, we urge relevant parties to pre-
sent a detailed account of the approach used alongside its
associated strengths and limitations, acknowledging that
other structures could have been considered.
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